Nos publications
Impact of Granulation Solvent on Release Performance of Dual Matrix Extended-Release Tablets of Highly Water Soluble Drugs Formulated using Compritol® 888 ATO and Methocel® as Release Retarding Agents
AAPS PharmSci360 – Boston (USA) - oct 2022
The purpose of this study is to evaluate the impact of different granulation solvents on the performance of dual extended- release matrix tablets, formulated using a combination of Compritol® 888 ATO and Methocel® K100M, with two model APIs:
- highly water-soluble high dose (1000 mg) Metformin Hydrochloride
- freely water-soluble low dose (95 mg) Metoprolol Succinate
Exploring the Potential of Compritol® 888 ATO for Abuse Deterrent Sustained Release Tablets
CRS Annual Meeting – Montreal (Canada) - jui 2022
Oral Drug Delivery for Modified Release Formulations
Wiley Library - Editors: Edmund S. Kostewicz, Maria Vertzoni, Heather A. E. Benson, Michael S. Roberts - avr 2022
In this eBook, Gattefossé describes the strategies for MR formulation development with Lipids (Part II - chapter 11)